RU2015108944A - Способ синтеза ингибиторов е1-активирующего фермента - Google Patents

Способ синтеза ингибиторов е1-активирующего фермента Download PDF

Info

Publication number
RU2015108944A
RU2015108944A RU2015108944/04A RU2015108944A RU2015108944A RU 2015108944 A RU2015108944 A RU 2015108944A RU 2015108944/04 A RU2015108944/04 A RU 2015108944/04A RU 2015108944 A RU2015108944 A RU 2015108944A RU 2015108944 A RU2015108944 A RU 2015108944A
Authority
RU
Russia
Prior art keywords
formula
compound
complex
hydrochloride salt
diazabicyclo
Prior art date
Application number
RU2015108944/04A
Other languages
English (en)
Russian (ru)
Inventor
Иан АРМИТЭЙДЖ
Эрик Л. Эллиот
Мэрианн ЛЭНГСТОН
Стивен П. Лэнгстон
Квентин Дж. Маккаббин
Хиротаке МИЗУТАНИ
Мэттью СТИРЛИНГ
Лэй ЧЖУ
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of RU2015108944A publication Critical patent/RU2015108944A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epoxy Compounds (AREA)
RU2015108944/04A 2007-08-02 2008-08-01 Способ синтеза ингибиторов е1-активирующего фермента RU2015108944A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96300807P 2007-08-02 2007-08-02
US60/963,008 2007-08-02
US6237808P 2008-01-25 2008-01-25
US61/062,378 2008-01-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010107471/04A Division RU2553476C2 (ru) 2007-08-02 2008-08-01 Способ синтеза ингибиторов е1-активирующего фермента

Publications (1)

Publication Number Publication Date
RU2015108944A true RU2015108944A (ru) 2015-08-20

Family

ID=40225413

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015108944/04A RU2015108944A (ru) 2007-08-02 2008-08-01 Способ синтеза ингибиторов е1-активирующего фермента
RU2010107471/04A RU2553476C2 (ru) 2007-08-02 2008-08-01 Способ синтеза ингибиторов е1-активирующего фермента

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2010107471/04A RU2553476C2 (ru) 2007-08-02 2008-08-01 Способ синтеза ингибиторов е1-активирующего фермента

Country Status (14)

Country Link
US (3) US8933225B2 (OSRAM)
EP (4) EP2540727B1 (OSRAM)
JP (3) JP5479336B2 (OSRAM)
KR (2) KR20100066475A (OSRAM)
CN (3) CN103483342B (OSRAM)
AU (1) AU2008305767B2 (OSRAM)
CA (2) CA2949336C (OSRAM)
ES (4) ES2758027T3 (OSRAM)
IL (2) IL203590A (OSRAM)
MX (1) MX2010001126A (OSRAM)
RU (2) RU2015108944A (OSRAM)
TW (2) TWI426077B (OSRAM)
WO (1) WO2009042013A1 (OSRAM)
ZA (1) ZA201000482B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001126A (es) 2007-08-02 2010-03-01 Millennium Pharm Inc Proceso para la sintesis de inhibidores de enzima de activacion de e1.
BRPI1012142A2 (pt) * 2009-05-14 2016-03-29 Millennium Pharm Inc sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato
US20120115892A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
UA116534C2 (uk) * 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104072381B (zh) * 2013-03-26 2017-04-12 安徽贝克联合制药有限公司 光学纯氨基醇盐酸盐的制备方法
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
NZ728162A (en) 2014-07-01 2023-06-30 Takeda Pharmaceuticals Co Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TW201628621A (zh) 2014-10-29 2016-08-16 千禧製藥公司 泛素活化酶抑制劑及輻射之施用
CN104974051A (zh) * 2015-06-30 2015-10-14 苏州开元民生科技股份有限公司 (1S,4R)-cis-4-氨基-2-环戊烯-1-甲醇盐酸盐的合成方法
CN106854208B (zh) * 2016-11-25 2019-04-09 成都柏睿泰生物科技有限公司 肿瘤抑制剂mln4924的合成方法
EP3684363A4 (en) 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
KR102018341B1 (ko) * 2018-06-21 2019-09-04 성균관대학교산학협력단 RNF170 및 pUL50을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
US20230246041A1 (en) * 2020-05-26 2023-08-03 Sony Semiconductor Solutions Corporation Ranging device
WO2022112951A1 (en) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138433A (en) * 1975-06-26 1979-02-06 Hoechst Aktiengesellschaft Process for preparing 1,2-oxa-phospholanes
US4081455A (en) * 1976-06-02 1978-03-28 Pfizer Inc. 6-Amino-2,2-dimethyl-3-cyanopenams
US4803272A (en) * 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
US4927830A (en) 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9205071D0 (en) 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
NZ294095A (en) 1994-09-09 1998-08-26 Wellcome Found Antiviral purine nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
US5912356A (en) 1995-09-11 1999-06-15 Glaxo Wellcome Inc. Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
BR9813480A (pt) 1997-12-17 2000-10-10 Biocryst Pharm Inc Compostos inibidores de neuraminidase de ciclopentano substituìdo, composição e métodos de inibição da neuraminidase do vìrus da influenza- e de tratamento de infecção por vìrus da influenza-
US6878716B1 (en) * 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6379552B1 (en) 1998-07-06 2002-04-30 Toray Industries, Inc. Method for resolving optical isomers
JP2000290201A (ja) * 1998-07-06 2000-10-17 Toray Ind Inc 光学異性体の分割方法
GB9907082D0 (en) 1999-03-26 1999-05-19 Chirotech Technology Ltd The preparation of carboxylic acid derivatives
CO5261573A1 (es) * 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
AU2576001A (en) 1999-12-10 2001-06-18 Glaxo Group Limited (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
BR0016415A (pt) * 1999-12-16 2002-12-24 Alcon Inc Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
AU2002358755A1 (en) 2001-12-21 2003-07-09 Schering Aktiengesellschaft Industrially applicable process for the sulfamoylation of alcohols and phenols
AU2003248708A1 (en) * 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2003105770A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101693695A (zh) * 2004-03-30 2010-04-14 大正制药株式会社 嘧啶衍生物以及与其应用有关的治疗方法
US20080096922A1 (en) 2004-04-06 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Novel Sulfonamide derivative
CA2471666C (en) 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
SI1848718T1 (sl) * 2005-02-04 2012-12-31 Millennium Pharmaceuticals, Inc. Inhibitorji E1 aktivacijskih enzimov
JP5231251B2 (ja) 2006-02-02 2013-07-10 ミレニアム ファーマシューティカルズ, インコーポレイテッド E1活性化酵素の阻害剤
CA2659894C (en) * 2006-08-08 2018-03-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MX2010001126A (es) 2007-08-02 2010-03-01 Millennium Pharm Inc Proceso para la sintesis de inhibidores de enzima de activacion de e1.
BRPI1012142A2 (pt) 2009-05-14 2016-03-29 Millennium Pharm Inc sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato

Also Published As

Publication number Publication date
IL203590A (en) 2017-03-30
JP2010535217A (ja) 2010-11-18
US20150080573A1 (en) 2015-03-19
TW201434851A (zh) 2014-09-16
CN101868461B (zh) 2013-09-25
CA2949336C (en) 2018-11-06
EP2540727B1 (en) 2018-07-25
CA2695193A1 (en) 2009-04-02
IL251372B (en) 2018-07-31
AU2008305767A1 (en) 2009-04-02
EP2178880A1 (en) 2010-04-28
EP2540727A1 (en) 2013-01-02
CN101868461A (zh) 2010-10-20
JP2014015483A (ja) 2014-01-30
US20090036678A1 (en) 2009-02-05
MX2010001126A (es) 2010-03-01
ES2684309T3 (es) 2018-10-02
JP2015025009A (ja) 2015-02-05
EP2178880B1 (en) 2017-10-04
TW200922937A (en) 2009-06-01
KR20100066475A (ko) 2010-06-17
CN106243111A (zh) 2016-12-21
KR20150064252A (ko) 2015-06-10
RU2010107471A (ru) 2011-09-10
KR101925902B1 (ko) 2018-12-06
IL251372A0 (en) 2017-05-29
WO2009042013A1 (en) 2009-04-02
EP2546256A3 (en) 2013-04-17
US20180079755A1 (en) 2018-03-22
US8933225B2 (en) 2015-01-13
AU2008305767B2 (en) 2014-07-31
EP2540726B1 (en) 2019-10-09
CN103483342A (zh) 2014-01-01
RU2553476C2 (ru) 2015-06-20
JP5479336B2 (ja) 2014-04-23
TWI426077B (zh) 2014-02-11
EP2546256B1 (en) 2019-10-09
CN103483342B (zh) 2016-08-31
CA2695193C (en) 2018-07-17
CA2949336A1 (en) 2009-04-02
US20150353555A9 (en) 2015-12-10
JP6148594B2 (ja) 2017-06-14
ES2757928T3 (es) 2020-04-30
EP2546256A2 (en) 2013-01-16
US10745404B2 (en) 2020-08-18
ZA201000482B (en) 2011-07-27
EP2540726A1 (en) 2013-01-02
CN106243111B (zh) 2019-07-23
ES2758027T3 (es) 2020-05-04
US9802938B2 (en) 2017-10-31
ES2655028T3 (es) 2018-02-16

Similar Documents

Publication Publication Date Title
RU2015108944A (ru) Способ синтеза ингибиторов е1-активирующего фермента
Cardona et al. New concise total synthesis of (+)-lentiginosine and some structural analogues
TW200633991A (en) Chemical compounds
DE602005023459D1 (de) Verfahren zur herstellung und reinigung von 2-hydrocarbyl-3,3-bis(4-hydroxyaryl-phthalimidin-monomeren
ATE381559T1 (de) Adamantan- und azabicyclooctan- und - nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
JP2014015483A5 (OSRAM)
NO20063841L (no) Krystallinske polymorfer av en CXC-kjemokinreseptorligand
DE502005004169D1 (de) Verfahren zur Herstellung flüssiger, lagerstabiler Carbodiimid- und/oder Uretonimingruppen aufweisender organischer Isocyanate mit niedriger Farbzahl
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
RU2007143505A (ru) Производные ацетилена
Murruzzu et al. Enantioselective synthesis of hydroxylated pyrrolidines via Sharpless epoxidation and olefin metathesis
RU2132850C1 (ru) Бициклические амидины и способ их получения
ATE553077T1 (de) Peptidaseinhibitoren
Çiçek et al. Synthesis and evaluation in vitro effects of some macrocyclic thiacrown ethers on erythrocyte carbonic anhydrase I and II
DE60236207D1 (de) Verfahren zur herstellung von phenserin und dessen analogon
Ando et al. A novel synthesis of the 2-amino-1H-imidazol-4-carbaldehyde derivatives and its application to the efficient synthesis of 2-aminoimidazole alkaloids, oroidin, hymenidin, dispacamide, monobromodispacamide, and ageladine A
ATE548375T1 (de) Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
EA200601898A1 (ru) Простой способ синтеза соединений баккатина iii
Chigorina et al. Novel reactions of 1-cyanoacetyl-3, 5-dimethylpyrazole (microreview)
Hu et al. A d-ribose-derived α-amino nitrile as a versatile intermediate for the collective synthesis of piperidine-type iminosugar C-glycosides
NO20016374D0 (no) Fremgangsmåte for fremstilling av et sensibilisert emulsjonssprengstoff
Manabe et al. Sulfonylcarbamate as a versatile and unique hydroxy-protecting group: a protecting group stable under severe conditions and labile under mild conditions
WO2007068417A3 (en) Process for the preparation of amines
RU2013150969A (ru) Промежуточное соединение для синтеза каспофунгина и способ его получения
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20180314